These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 28863016)

  • 1. Oligometastatic prostate cancer: shaping the definition with molecular imaging and an improved understanding of tumor biology.
    Joice GA; Rowe SP; Pienta KJ; Gorin MA
    Curr Opin Urol; 2017 Nov; 27(6):533-541. PubMed ID: 28863016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.
    Rowe SP; Gorin MA; Allaf ME; Pienta KJ; Tran PT; Pomper MG; Ross AE; Cho SY
    Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):223-30. PubMed ID: 27136743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The biology of prostate cancer metastases: does oligo differ from polymetastatic?
    Sonpavde G
    Curr Opin Urol; 2017 Nov; 27(6):542-546. PubMed ID: 28786848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time.
    Dhondt B; De Bleser E; Claeys T; Buelens S; Lumen N; Vandesompele J; Beckers A; Fonteyne V; Van der Eecken K; De Bruycker A; Paul J; Gramme P; Ost P
    World J Urol; 2019 Dec; 37(12):2557-2564. PubMed ID: 30578441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oligometastatic prostate cancer treatment.
    Rossetti S; Di Napoli M; Pisano C; C Cecere S; Tambaro R; Ventriglia J; Passarelli A; Iovane G; Feroce F; Lastoria S; Di Gennaro F; Muto P; Borzillo V; Di Franco R; Perdonà S; Quarto G; Pignata S
    Future Oncol; 2021 Oct; 17(29):3893-3899. PubMed ID: 34296622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The phytological future of prostate cancer staging: PSMA-PET and the dandelion theory.
    Sathianathen NJ; Geurts N; Nair R; Lawrentschuk N; Murphy DG; Lamb AD
    Future Oncol; 2017 Aug; 13(20):1801-1807. PubMed ID: 28762288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging of Prostate Cancer Using
    Singh A; Kulkarni HR; Baum RP
    PET Clin; 2017 Apr; 12(2):193-203. PubMed ID: 28267453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
    Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
    Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The role of PSMA PET-CT in patients with metastatic prostate cancer].
    von Hardenberg J; Büsing KA; Nuhn P; Ritter M
    Urologe A; 2017 Nov; 56(11):1410-1416. PubMed ID: 28980045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Applications of Molecular Imaging in the Management of Prostate Cancer.
    Gorin MA; Rowe SP; Denmeade SR
    PET Clin; 2017 Apr; 12(2):185-192. PubMed ID: 28267452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Biology of Oligometastatic Prostate Cancer: A Different Beast than Polymetastatic Prostate Cancer.
    Kucharczyk MJ; Gravis G; Niazi T
    Eur Urol Focus; 2019 Mar; 5(2):117-118. PubMed ID: 30527643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What Is Oligometastatic Prostate Cancer?
    Fraser M; Koontz B; Emmenegger U; De Meerleer G; Khoo V; Feng F; Corcoran NM; Hovens CM; Tran PT; Ost P; Boutros PC;
    Eur Urol Focus; 2019 Mar; 5(2):159-161. PubMed ID: 30642810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer.
    Rowe SP; Gage KL; Faraj SF; Macura KJ; Cornish TC; Gonzalez-Roibon N; Guner G; Munari E; Partin AW; Pavlovich CP; Han M; Carter HB; Bivalacqua TJ; Blackford A; Holt D; Dannals RF; Netto GJ; Lodge MA; Mease RC; Pomper MG; Cho SY
    J Nucl Med; 2015 Jul; 56(7):1003-1010. PubMed ID: 26069305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New aspects of molecular imaging in prostate cancer.
    Ceci F; Castellucci P; Cerci JJ; Fanti S
    Methods; 2017 Nov; 130():36-41. PubMed ID: 28711565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel imaging in advanced prostate cancer.
    Goldberg H; Hamilton RJ
    Curr Opin Support Palliat Care; 2017 Sep; 11(3):238-246. PubMed ID: 28590314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography for Prostate Cancer: Distribution of Disease and Implications for Radiation Therapy Planning.
    Gupta SK; Watson T; Denham J; Shakespeare TP; Rutherford N; McLeod N; Picton K; Ainsworth P; Bonaventura T; Martin JM
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(3):701-709. PubMed ID: 29280465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group.
    Lecouvet FE; Oprea-Lager DE; Liu Y; Ost P; Bidaut L; Collette L; Deroose CM; Goffin K; Herrmann K; Hoekstra OS; Kramer G; Lievens Y; Lopci E; Pasquier D; Petersen LJ; Talbot JN; Zacho H; Tombal B; deSouza NM
    Lancet Oncol; 2018 Oct; 19(10):e534-e545. PubMed ID: 30303127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in Management of Oligometastatic Hormone-Sensitive Prostate Cancer.
    Kothari G; Ost P; Cheung P; Blanchard P; Tree AC; van As NJ; Lo SS; Moghanaki D; Loblaw A; Siva S
    Curr Oncol Rep; 2019 Mar; 21(5):43. PubMed ID: 30919165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls.
    Hofman MS; Hicks RJ; Maurer T; Eiber M
    Radiographics; 2018; 38(1):200-217. PubMed ID: 29320333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current use of PSMA-PET in prostate cancer management.
    Maurer T; Eiber M; Schwaiger M; Gschwend JE
    Nat Rev Urol; 2016 Apr; 13(4):226-35. PubMed ID: 26902337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.